Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$248.35
+1.8%		$230.01
$151.83
▼
$258.78
$36.71B0.11.35 million shs1.00 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$53.63
+1.7%		$39.18
$23.62
▼
$59.97
$33.47B0.736.03 million shs7.83 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$131.73
+2.8%		$115.68
$56.75
▼
$138.00
$11.25B2.04984,764 shs784,611 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$192.28
+8.2%		$196.88
$58.91
▼
$224.31
$41.21B1.442.15 million shs4.50 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
+1.81%-2.08%+11.79%+19.43%+61.87%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+1.69%-6.01%+46.33%+71.62%+83.73%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+2.82%+4.03%+21.58%+22.52%+119.95%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+8.24%+0.51%-4.28%-6.27%+224.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$248.35
+1.8%		$230.01
$151.83
▼
$258.78
$36.71B0.11.35 million shs1.00 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$53.63
+1.7%		$39.18
$23.62
▼
$59.97
$33.47B0.736.03 million shs7.83 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$131.73
+2.8%		$115.68
$56.75
▼
$138.00
$11.25B2.04984,764 shs784,611 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$192.28
+8.2%		$196.88
$58.91
▼
$224.31
$41.21B1.442.15 million shs4.50 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
+1.81%-2.08%+11.79%+19.43%+61.87%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+1.69%-6.01%+46.33%+71.62%+83.73%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+2.82%+4.03%+21.58%+22.52%+119.95%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+8.24%+0.51%-4.28%-6.27%+224.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$252.341.61% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.92
Moderate Buy$53.61-0.04% Downside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.89
Moderate Buy$139.165.64% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.92
Moderate Buy$263.1536.86% Upside

Current Analyst Ratings Breakdown

Latest KYMR, RVMD, BIIB, and GMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/6/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$280.00 ➝ $350.00
11/5/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$250.00 ➝ $270.00
11/5/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$260.00 ➝ $321.00
11/5/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$210.00 ➝ $222.00
11/5/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$241.00 ➝ $261.00
11/5/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$275.00 ➝ $298.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$280.00 ➝ $300.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$251.00 ➝ $270.00
11/2/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$139.00 ➝ $170.00
10/30/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$42.00 ➝ $57.00
10/30/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$58.00 ➝ $80.00
(Data available from 11/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.71$22.64 per share10.97$128.01 per share1.94
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B9.00$1.61 per share33.32$9.10 per share5.89
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$39.21M286.81N/AN/A$18.91 per share6.97
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,559.01N/AN/A$11.20 per share17.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.3421.0815.532.823.37%9.38%5.69%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2741.2531.732.1116.97%13.96%6.47%N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$311.35M-$3.62N/AN/AN/A-285.33%-22.39%-20.48%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$9.11N/AN/AN/AN/A-84.51%-51.97%N/A

Latest KYMR, RVMD, BIIB, and GMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.36$0.56+$0.20$0.5510$1.20 billion$1.19 billion
11/4/2026Q3 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.35-$1.90+$0.45-$1.90$25.58 million$197.56 million
10/29/2026Q3 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$1.26-$1.32-$0.06-$1.32$3.28 million$1.35 million
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
11.13
11.13
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.44
8.36
11.38

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
15.98%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
27385.37 million71.73 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Raised to Hold at Wall Street Zen
November 7 at 4:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183639
Revolution Medicines (NASDAQ:RVMD) Upgraded to "Hold" at Wall Street Zen
November 7 at 3:42 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-nasdaq-rvmd-upgraded-to-hold-at-wall-street-zen-2026-11-07/
Financial Survey: Revolution Medicines (NASDAQ:RVMD) and Rigel Pharmaceuticals (NASDAQ:RIGL)
November 7 at 2:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183108
Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $350.00
November 6 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-nasdaq-rvmd-price-target-raised-to-35000-2026-11-06/
Research Analysts Set Expectations for RVMD FY2029 Earnings
November 6 at 7:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-research-analysts-set-expectations-for-rvmd-fy2029-earnings-2026-11-06/
Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript
November 5 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-q3-2026-174349475.html
TD Cowen Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock
November 5 at 3:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-td-cowen-forecasts-strong-price-appreciation-for-revolution-medicines-nasdaq-rvmd-stock-2026-11-05/
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It
November 5 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4963370-revolution-medicines-q3-earnings-stellar-company-and-drug-but-market-knows-it
Revolution Medicines (NASDAQ:RVMD) Stock Gets Price Target Bump from Royal Bank Of Canada
November 5 at 2:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-nasdaq-rvmd-stock-gets-price-target-bump-from-royal-bank-of-canada-2026-11-05/
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
November 5 at 2:21 PM  |  zacks.comhttps://www.zacks.com/stock/news/3024765/rvmd-q3-earnings-sales-beat-estimates-on-encouraging-rasonque-uptake?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-3024765
RBC Raises Price Target on Revolution Medicines to $321 From $260, Keeps Outperform Rating
November 5 at 12:20 PM  |  marketscreener.comM
Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $222.00
November 5 at 12:05 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-nasdaq-rvmd-price-target-raised-to-22200-2026-11-05/
Revolution Medicines' (RVMD) "Buy" Rating Reiterated at Truist Financial
November 5 at 11:29 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-rvmd-buy-rating-reiterated-at-truist-financial-2026-11-05/
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Guggenheim Analyst Says
November 5 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-nasdaq-rvmd-stock-price-expected-to-rise-guggenheim-analyst-says-2026-11-05/
Revolution Medicines (NASDAQ:RVMD) Stock Crosses Above 50 Day Moving Average - Here's What Happened
November 5 at 7:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-revolution-medicines-nasdaq-rvmd-stock-crosses-above-50-day-moving-average-heres-what-happened-2026-11-05/
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call
November 5 at 1:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/transcript-what-revolution-medicines-rvmd-said-on-its-q3-earnings-call-2026-11-05/
Revolution Medicines (NASDAQ:RVMD) Posts Earnings Results, Beats Estimates By $0.45 EPS
November 4 at 7:10 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/earnings-revolution-medicines-nasdaq-rvmd-posts-earnings-results-beats-estimates-by-045-eps-2026-11-04/
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates
November 4 at 6:16 PM  |  zacks.comhttps://www.zacks.com/stock/news/3023449/revolution-medicines-inc-rvmd-reports-q3-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-3023449
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
November 4 at 4:02 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395785/0/en/revolution-medicines-reports-third-quarter-2026-financial-results-and-update-on-corporate-progress.html
Revolution Medicines (RVMD) Stock Forecast & Price Target
November 4 at 3:56 PM  |  tipranks.comhttps://www.tipranks.com/stocks/rvmd/forecast
Revolution Medicines, Inc. $RVMD Stock Bought by Sumitomo Mitsui Trust Group Inc.
November 4 at 5:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-stock-bought-by-sumitomo-mitsui-trust-group-inc-2026-11-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biogen stock logo

Biogen NASDAQ:BIIB

$248.35 +4.42 (+1.81%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$248.45 +0.10 (+0.04%)
As of 11/6/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$53.63 +0.89 (+1.69%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$53.60 -0.03 (-0.06%)
As of 11/6/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$131.73 +3.61 (+2.82%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$131.58 -0.15 (-0.11%)
As of 11/6/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$192.28 +14.63 (+8.24%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$193.25 +0.97 (+0.50%)
As of 11/6/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas